Totally three articles focusing on "autoantibody detection of multitiple sclerosis, genetic correlation and clinical and pathological manifestations of multiple sclerosis in Chinese population" are published in three issues. We hope that our readers find these papers useful to their research.

**Abstract**

This study sought to elucidate the role of the *Pvu*II and *Xba*I polymorphisms of the estrogen receptor gene in 74 Chinese patients with multiple sclerosis, and 95 ethnicity-matched controls, using polymerase chain reaction-restriction fragment-length polymorphism analysis. The results revealed that the P allele of *Pvu*II was significantly more prevalent in multiple sclerosis patients compared with controls (*P* = 0.019). While distribution frequencies were significantly increased in female multiple sclerosis patients compared with female controls (*P* = 0.044), no significant difference was observed between male patients and controls (*P* \> 0.05). Frequencies of Ppxx genotypes were significantly higher in multiple sclerosis patients compared with controls (24.3% vs. 12.8%, *P* = 0.025). Genotypes and alleles of the estrogen receptor were not associated with age, number of attacks or expanded disability status scale scores of patients with multiple sclerosis. These findings indicate that the *Pvu*II but not the *Xba*I polymorphism in the estrogen receptor gene is associated with susceptibility to multiple sclerosis in the Chinese population. In addition, women with P allele appear to be particularly susceptible to multiple sclerosis.
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**Abstract**

Little information is available regarding comparisons of Devic\'s neuromyelitis optica (DNMO) patients between China and other countries, as well as clinical manifestations of Chinese patients with DNMO and multiple sclerosis. The present study performed a multi-center, pathological, retrospective analysis. All seven Chinese patients with DNMO exhibited abrupt onset of vision disturbance, with a disease course of 3 days to 9 years. DNMO recurred in two of the patients. Demyelinating lesions were observed in all patients, with necrotic lesions and gitter cells in five patients, collagenous hyperplasia in one patient, and perivascular inflammatory cell infiltration in six patients. Comparison between Chinese and Caucasian DNMO patients revealed no significant differences in age at onset, clinical onset, duration, or interval between optic neuritis and myelitis. Compared with Chinese multiple sclerosis patients, Chinese DNMO patients presented with fewer recurrences, higher occurrence of necrosis, perivascular inflammatory cell infiltration and gitter cells, and a lower occurrence of collagenous hyperplasia. The results suggested there was no difference in DNMO clinical features between Chinese and Caucasian patients. However, the clinical and pathological features of DNMO were different compared with multiple sclerosis in Chinese patients. Results suggested that the characteristics of DNMO in Chinese patients were significantly different than multiple sclerosis.
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**Abstract**

Humoral autoimmunity in patients with multiple sclerosis is often asymptomatic and transient during interferon therapy. To analyze the frequency of positivity to autoantibodies in multiple sclerosis patients, and to clarify whether it is modified by immunomodulating therapy. We selected 169 multiple sclerosis patients. Individuals were mainly outpatients and were usually tested yearly for autoantibodies. Patients with previous immunological diseases were excluded from statistical evaluation. The frequency of positivity was calculated in patients grouped for gender, multiple sclerosis clinical parameters, magnetic resonance imaging features and disease modifying therapy. A total of 113 patients were treated with beta interferons. The overall prevalence of autoantibodies within 3 years was 47.3%. In multiple sclerosis patients who were untreated or treated with drugs other than interferons, the prevalence was higher, and greater positivity to autoantibodies was seen in patients treated with interferons \[odds ratio (95% confidence interval), 2.87 (1.5 -- 5.2), *P* \< 0.05 -- 0.01\]. Multiple regression analysis showed a significant association of the positivity to autoantibodies with interferon therapy, rather than gender, relapse or magnetic resonance imaging. The findings indicated that interferon therapy is associated with significantly higher frequency of autoantibo dies in patients with multiple sclerosis. The differences among the therapies are not influenced by other variables such as gender or clinical pattern.
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